Novel vaccines targeting dendritic cells
This article was originally published in Start Up
Vaccibody AS’ platform can develop vaccines that can drive the immune response in specific directions and thus optimize the vaccine for different diseases – for example, toward the T-cell cell-mediated response for therapeutic vaccines, or the B-cell antibody-mediated response for prophylactic vaccines. The start-up’s lead vaccine is a therapeutic one, targeting precancerous lesions and malignancies in the cervix caused by human papillomavirus. Safety and toxicity studies are under way, and clinical trials are planned for early 2014.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.